Text Size

Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol). (PATROL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00891124
First received: April 28, 2009
Last updated: November 2, 2009
Last verified: November 2009
History of Changes
  Purpose

This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care nationwide.


Condition
Glycemia
Hypertension
Hyperlipidemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multi-center, Prospective, Observational Study to Assess the Effect of Patient Education Related to CV Risk Factors in Type 2 Diabetes Mellitus

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline [ Time Frame: At baseline and Endpiont (after 2months) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The treatment goal of risk factors is based on ADA guideline. [ Time Frame: At baseline and Endpiont (after 2months) ] [ Designated as safety issue: No ]

Enrollment: 4045
Study Start Date: May 2009
Study Completion Date: October 2009
Groups/Cohorts
1
Type II DM and Hypertension and/or Hyperlipidemia

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Type II DM and Hypertension and/or Hyperlipidemia

Criteria

Inclusion Criteria:

  • Patients who had been diagnosed with type II diabetes mellitus
  • Patients with hypertension and / or hyperlipidemia
  • Patients who had agreed to Informed

Exclusion Criteria:

  • Patients who had been diagnosed with type I diabetes mellitus
  • Patients with neither hypertension and hyperlipidemia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00891124

Locations
Korea, Republic of
Research Site
Busan, Korea, Republic of
Research Site
Cheiju, Korea, Republic of
Research SIte
Daegu, Korea, Republic of
Research Site
Gwangju, Korea, Republic of
Research Site
Hongsung, Korea, Republic of
Research Site
Seoul, Korea, Republic of
Research Site
Sungman, Korea, Republic of
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Joonwoo Bahn ASTRAZENECA, Korea Medical Department
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00891124     History of Changes
Other Study ID Numbers: NIS-CKR-DUM-2009/2
Study First Received: April 28, 2009
Last Updated: November 2, 2009
Health Authority: Korea: Food and Drug Administration

Keywords provided by AstraZeneca:
Hypertension
Type II DM
Hyperlipidemia
 Glycemia
ADA 2008 guideline
Patient Consultation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Hyperlipidemias
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
 Endocrine System Diseases
Dyslipidemias
Lipid Metabolism Disorders
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 22, 2013